Increased prevalence of doxycycline low‐susceptible Cutibacterium acnes isolated from acne patients in Japan caused by antimicrobial use and diversification of tetracycline resistance factors
- 17 May 2021
- journal article
- research article
- Published by Wiley in The Journal of Dermatology
- Vol. 48 (9) , 1365-1371
Abstract
The prevalence of antimicrobial‐resistant Cutibacterium acnes is an important concern for the antimicrobial treatment of acne vulgaris. We hypothesized that antimicrobial treatment regimens for acne vulgaris would change following the revisions in the Japanese acne treatment guidelines, which added a statement regarding appropriate antimicrobial usage. Here, we studied the changes in antimicrobial use and antimicrobial‐resistant C. acnes isolated from acne patients. A total of 127 C. acnes isolates collected from 212 patients with acne between 2013 and 2018 were used. Roxithromycin and clindamycin resistance rates were approximately 50% and 40%, respectively. In contrast, the prevalence of low doxycycline‐susceptible strains (minimum inhibitory concentration [MIC] ≥8 μg/mL) in 2018 (17.4%) was 5.6‐fold higher than that in 2013 (3.1%). Although the number of patients with severe and moderate acne did not change, the number of patients with a history of oral tetracycline use increased. The incidence of low doxycycline‐susceptible strains was high in patients with a history of oral tetracycline use. The prevalence of strains with a 16S rRNA mutation, which confers reduced susceptibility to tetracyclines, increased by 8.6‐fold (12.1%) from 2016 to 2018 in comparison with the previously revised guidelines (1.4%). Furthermore, the prevalence of low susceptibility strains with two resistance factors, 16S rRNA mutation and ribosomal S10 protein substitution, also increased. Approximately 10% of strains had the exogenous resistance gene, tet(W) (2013 to 2015, 10.1%; 2016 to 2018, 8.6%), and these strains showed different susceptibility to doxycycline dependent on the expression of tet(W) (MIC range 0.5–8 μg/mL). Our data show that the antimicrobial resistance pattern in C. acnes changes according to the trend of antimicrobial usage for acne treatment. Therefore, we should pay heed to the rapid dissemination of tetracycline resistance in C. acnes owing to acquisition of 16S rRNA mutation and tet(W).Keywords
This publication has 17 references indexed in Scilit:
- Transferable Multidrug-Resistance Plasmid Carrying a Novel Macrolide-Clindamycin Resistance Gene, erm (50), in Cutibacterium acnesAntimicrobial Agents and Chemotherapy, 2020
- Transconjugation of erm(X) conferring high-level resistance of clindamycin for Cutibacterium acnesJournal of Medical Microbiology, 2019
- Japanese Dermatological Association Guidelines: Guidelines for the treatment of acne vulgaris 2017The Journal of Dermatology, 2018
- Guidelines for the management of acne: recommendations from a French multidisciplinary groupBritish Journal of Dermatology, 2017
- Antimicrobial susceptibility and phylogenetic analysis ofPropionibacterium acnesisolated from acne patients in Japan between 2013 and 2015The Journal of Dermatology, 2017
- Propionibacterium acnes is developing gradual increase in resistance to oral tetracyclinesJournal of Medical Microbiology, 2017
- A novel 23S rRNA mutation in Propionibacterium acnes confers resistance to 14-membered macrolidesJournal of Global Antimicrobial Resistance, 2016
- Antibiotic resistance toPropionobacterium acnes: worldwide scenario, diagnosis and managementExpert Review of Anti-infective Therapy, 2015
- Relationship between the severity of acne vulgaris and antimicrobial resistance of bacteria isolated from acne lesions in a hospital in JapanJournal of Medical Microbiology, 2014
- Staphylococcus epidermidis in the human skin microbiome mediates fermentation to inhibit the growth of Propionibacterium acnes: implications of probiotics in acne vulgarisApplied Microbiology and Biotechnology, 2013